Multiple sources indicate that the National Reform and Development Commission will initiate a new round of drug price cuts this year, targeting cancer drugs, blood products, immunomodulating drugs, and other high profitmargin medicines. The sources indicated that price cuts may exceed 20 percent, although blood products in severe shortage may not be affected. Additionally, the 700 price cuts target cancer drugs and blood products with high profit margins. An official from the Ministry of Health disclosed that the National Essential Drug Catalogue may be expanded to cover a total of 700 types of drugs, significantly more than the 500 categories originally anticipated. The MOH official noted that the current essential drug list does not cover blood products that are listed in the World Health Organization list of essential drugs. The expansion of the Essential Drug Catalogue is expected to be targeted at the needs of Tier Two and Three hospitals.
Register Now As you are not an existing subscriber please register for your free daily legal newsfeed service.Register
If you have any questions about the service please contact email@example.com or call Lexology Customer Services on +44 20 7234 0606.
New round of drug price cuts expected, maximum cut to be more than 20 percent (Xinhua Net 2012-07-27) --- July 27, 2012
- Reed Smith LLP
- Jay J. Yan, Hugh Scogin, John Tan, Katherine Yang, May Ling Wong and Gordon B. Schatz
- August 8 2012
If you are interested in submitting an article to Lexology, please contact Andrew Teague at firstname.lastname@example.org.